Regents Professor Washington State University Pullman, Washington, United States
Presentation Description / Summary: P-glycoprotein (P-gp) plays a key role in the disposition of substrate drugs. P-gp deficiency, either intrinsic or acquired, renders affected cats highly susceptible to adverse effects of drugs at doses well-tolerated in animals with normal P-gp function. A recently introduced parasiticide serves as a case in point. The author is aware of dozens of cases of severe and fatal neurotoxicosis when cats were treated with label doses of the products. The speaker proposes 3 sites where the body fails, without P-gp, to protect itself from potentially toxic P-gp substrates drugs, and will describe 3 distinct clinical consequences that can result. This information can help veterinarians prevent these adverse drug reactions in patients with P-gp deficiency (preferably) or help the veterinary team manage adverse drug reactions that have occurred because of P-gp deficiency.
Learning Objectives:
describe any breed predilections and relative frequencies of the feline MDR1 mutation in the general population
describe two different ways P-glycoprotein deficiency can occur in cats
• To name commonly used P-glycoprotein substrate drugs that can cause adverse drug reactions in cats.
understand treatment strategies for cats experiencing eprinomectin neurotoxicosis
